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899Comparison of Transfemoral Transcatheter
Aortic Valve Replacement Performed in the
Catheterization Laboratory (Minimalist Approach)
Versus Hybrid Operating Room (Standard Approach)Outcomes and Cost AnalysisABSTRACTOBJECTIVES The aim of this study was to compare transfemoral transcatheter aortic valve replacement (TF TAVR)
performed in a catheterization laboratory (minimalist approach [MA]) with TF TAVR performed in a hybrid operating room
(standard approach [SA]).
BACKGROUND A MA-TF TAVR can be performed without general anesthesia, transesophageal echocardiography, or a
surgical hybrid room. The outcomes and cost of MA-TF TAVR compared with those of the SA have not been described.
METHODS Patients who underwent elective, percutaneous TF TAVR using the Edwards Sapien valve (Edwards Life-
sciences, Irvine, California) were studied. Baseline characteristics, outcomes, and hospital costs of MA-TF TAVR and
SA-TF TAVR were compared.
RESULTS A total of 142 patients were studied (MA-TF TAVR, n¼ 70 and SA-TF TAVR, n¼ 72). There were no differences
in baseline comorbidities (Society of Thoracic Surgeons score, 10.6  4.3 vs. 11.4  5.8; p ¼ 0.35). All procedures in the
MA-TF TAVR group were successful; 1 patient was intubated. Three patients in the SA-TF TAVR group had procedure-
related death. Procedure room time (150  48 min vs. 218  56 min, p < 0.001), total intensive care unit time (22 h vs.
28 h, p<0.001), length of stay from procedure to discharge (3 days vs. 5 days, p<0.001), and cost ($45,485 14,397 vs.
$55,377  22,587, p < 0.001) were signiﬁcantly less in the MA-TF TAVR group. Mortality at 30 days was not signiﬁcantly
different in the MA-TF TAVR group (0 vs. 6%, p¼ 0.12) and 30-day stroke/transient ischemic attack was similar (4.3% vs.
1.4%, p¼ 0.35). Moderate or severe paravalvular leak and device success were similar in the MA-TF TAVR and SA-TF TAVR
groups (3% vs. 5.8%, p ¼ 0.4 and 90% vs. 88%, p ¼ 0.79, respectively) at 30 days. At a median follow-up of 435 days,
there was no signiﬁcant difference in survival (MA-TF TAVR, 83% vs. SA-TF TAVR, 82%; p ¼ 0.639).
CONCLUSIONS MA-TF TAVR can be performed with minimal morbidity and mortality and equivalent effectiveness
compared with SA-TF TAVR. The shorter length of stay and lower resource use with MA-TF TAVR signiﬁcantly lowers
hospital costs. (J Am Coll Cardiol Intv 2014;7:898–904) © 2014 by the American College of Cardiology Foundation.A s experience with transcatheter aortic valvereplacement (TAVR) has increased, somecenters have performed transfemoral (TF)
TAVR in a standard cardiac catheterization laboratory
without general anesthesia or transesophageal echo-
cardiography (TEE) (1–3). In this study, we compare
the safety, efﬁcacy, and cost of such a minimalist
approach (MA) with the current standard approach
(SA) performed in a hybrid operating room.
METHODS
We reviewed all cases of TAVR at our center from
November 2010 to September 2013 for patients whounderwent elective percutaneous treatment with
the Edwards Sapien valve (22- and 24-French delivery
systems, Edwards Lifesciences, Irvine, California).
The study was approved and performed in accordance
with the regulations of the hospital institutional re-
view board (Emory University, Atlanta, Georgia).
In May 2012, an MA-TF strategy was adopted for TF
TAVR at our institution. TF TAVR procedures were
performed thereafter using theMA except in rare cases
when the patient was unable to lie down for the pro-
cedure or the schedule prohibited use of the catheter-
ization laboratory. MA-TF used local anesthesia,
minimal conscious sedation, fully percutaneous
access site entry and closure, and transthoracic
ABBR EV I A T I ON S
AND ACRONYMS
ICU = intensive care unit
MA = minimalist approach
PCI = percutaneous coronary
intervention
SA = standard approach
TAVR = transcatheter aortic
valve replacement
TEE = transesophageal
echocardiography
TF = transfemoral
TTE = transthoracic
echocardiography
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900echocardiography (TTE). A sonographer per-
formed the TTE, and an attending imaging
cardiologist was present to aid with the
placement and post-deployment function of
the TAVR. Procedures were performed in a
standard cardiac catheterization laboratory. A
catheterization laboratory nurse, under the
direction of the operating physician, admin-
istered sedation with fentanyl and mid-
azolam. A condom catheter was used for men,
and some women had Foley catheters placed.
Pulmonary artery catheters were not used for
monitoring. Femoral access was obtained us-
ing a micropuncture kit with ﬂuoroscopic
guidance, which included a roadmap angio-gram performed from the contralateral iliac artery for
placement of the delivery sheath. Pre-closure was
performed with Perclose devices (Abbott Vascular,
Abbott Park, Illinois). Two Perclose devices were
placed at slight angulation before sheath placement
and a third Perclose device was placed after sheath
removal. Wire and catheter techniques were used to
align the delivery system through the center of the
stenotic valve and allow for coaxial deployment. Pa-
tients early in the experience were transferred from
the catheterization laboratory to an intensive care unit
(ICU). All subsequent patients were sent to a regular
telemetry ﬂoor.
The SA performed in a hybrid operating room
included endotracheal intubation, bladder catheteri-
zation, pulmonary artery catheter hemodynamic
monitoring, general anesthesia, TEE, and percuta-
neous femoral artery access and closure. An anesthe-
siologist administered general anesthesia. Patients
were transferred from the operating room to an ICU for
extubation and recovery.
Baseline characteristics, procedural and outcomes
data were expressed using Society of Thoracic Sur-
geons or Valve Academic Research Consortium-2
deﬁnitions when applicable. Cost was calculated us-
ing Sunrise EPSi software (Enterprise Performance
Systems, Inc., Allscripts, Chicago, Illinois) for the in-
dex procedure hospitalization, which included
$32,500 for the valve (standard cost for the Edwards
Sapien commercial valve in the United States).
STATISTICAL METHODS. Continuous variables are
presented as mean  SD and categorical variables as
proportion (%). Non-normally distributed data are
presented as median (interquartile range). The Stu-
dent t test, chi-square analyses, or Fisher exact test
were performed when appropriate. Mann-Whitney
2-independent sample tests were performed for
comparison of non-normally distributed data across 2groups. Robust regression analysis was performed to
determine univariate correlates of the length of stay
and the cost variables given their non-normal distri-
bution. Univariate correlates with p < 0.05 were
included in multivariable models to determine inde-
pendent predictors of both cost and length of stay.
Survival estimates were compared between MA-TF
and SA-TF using Kaplan-Meier survival analysis
after groups were balanced for length of follow-up.
p Values <0.05 from 2-sided tests were considered
statistically signiﬁcant. Statistical analyses were per-
formed using SAS statistical software version 9.3 (SAS
Institute, Cary, North Carolina).
RESULTS
From November 2010 to September 2013, 142 patients
with aortic stenosis underwent percutaneous TF
TAVR at our center using the Edwards Sapien valve.
Patients implanted with the SAPIEN XT or SAPIEN 3
valve (Edwards Lifesciences) and patients who un-
derwent emergent TAVR for cardiogenic shock were
not included in this analysis.
BASELINE PATIENT CHARACTERISTICS. MA-TF was
performed in 70 and SA-TF in 72 patients. Baseline
patient characteristics and comorbidities were similar
between the 2 groups (Table 1), with both groups hav-
ing a mean patient age older than 80 years and mean
Society of Thoracic Surgeons mortality risk score of
>10%. All patients were classiﬁed as high risk or
inoperable for surgical aortic valve replacement by the
structural heart team (cardiothoracic surgeon, inter-
ventional cardiologist, cardiac imager, and structural
heart mid-level provider/coordinator). A higher per-
centage of patients in the MA-TF group had previous
mitral valve replacement (10% vs. 1%, p ¼ 0.038).
Baseline B-type natriuretic peptide level was higher in
the SA-TF group (310 pg/l vs. 547 pg/l, p ¼ 0.01).
PROCEDURE EVOLUTION. After we started the MA in
May 2012, the majority of TF TAVR cases were per-
formed as MA-TF TAVR (86%) (Fig. 1). In the 11 cases of
SA-TF performed afterMay 2012, 8 patients underwent
SA-TF because of scheduling issues and early adapta-
tion of the MA-TF technique. Two patients underwent
SA-TF because of concomitant morbid obesity (>100
kg) and severe lung disease with inability to lie down
and breath comfortably. We performed SA-TF in
another patient with previous vascular cut downs and
abdominal endografts. Complications developed in
none of these 3 patients. Although we performed MA-
TF on patients with decompensated heart failure or
poor lung function using a wedge to elevate their head
and back, we did not think we could safely access and
TABLE 1 Baseline Patient Characteristics
Characteristic
Minimalist Approach
(n ¼ 70)
Standard Approach
(n ¼ 72) p Value
Age, yrs 82  8 83  8 0.58
Male sex 43 (61) 38 (53) 0.29
STS PROM score, % 10.6  4.3 11.4  5.8 0.35
Body mass index 27  5 28  6 0.23
Diabetes 30 (43) 32 (44) 0.85
Hypertension 69 (99) 70 (97) 0.58
Angina 17 (24) 16 (22) 0.84
NYHA functional class III or IV 61 (87) 64 (89) 0.45
Need for urgent procedure 2 (3) 2 (3) 1.00
Severe COPD 11 (16) 9 (13) 0.93
Sleep apnea 6 (9) 7 (10) 0.81
Coronary artery disease 58 (83) 57 (81) 0.91
Previous myocardial infarction 21 (30) 27 (38) 0.34
Previous CABG 21 (40) 29 (40) 1.00
Previous mitral valve surgery 7 (10) 1 (1) 0.038
Previous PCI 53 (76) 55 (76) 0.92
Previous BAV 20 (29) 20 (28) 0.26
End-stage renal disease 4 (6) 4 (6) 1.00
Cerebrovascular disease 22 (31) 26 (36) 0.55
Previous TIA or CVA 14 (20) 20 (28) 0.27
Atrial ﬁbrillation or ﬂutter 33 (47) 32 (44) 1.00
Peripheral vascular disease 15 (21) 17 (24) 0.75
Immunocompromised 12 (17) 7 (10) 0.19
Liver disease 5 (7) 2 (3) 0.46
Echocardiogram
LVEF, % 49  15 49  15 0.82
RV dysfunction (moderate-severe) 9 (13) 11 (15) 0.67
Functional bicuspid valve 5 (7) 4 (6) 0.69
Aortic valve area, cm2 0.7  0.2 0.7  0.1 0.14
Mean aortic gradient, mm Hg 43  13 46  12 0.20
Grade 3/4 MR 32 (46) 44 (61) 0.11
Grade 3/4 TR 32 (46) 38 (53) 0.44
DSE performed 10 (14) 11 (15) 0.86
Blood
Hemoglobin, g/dl 11.5  1.7 11.2  1.3 0.22
Creatinine, mg/dl* 1.3 (1.0–1.52) 1.2 (1.0–1.5) 0.51
BNP, pg/l* 310 (182–739) 547 (328–1297) 0.01
Troponin I, ng/ml* 0.03 (0.02–0.06) 0.03 (0.02–0.05) 0.75
Values are number (%), mean  SD for normally distributed numeric variables, or median (interquartile range)
for non-normally distributed variables. *Non-normally distributed variables.
BAV ¼ balloon aortic valvuloplasty; BNP ¼ B-type natriuretic peptide; CABG ¼ coronary artery bypass grafting;
COPD ¼ chronic obstructive pulmonary disease; CVA ¼ cerebrovascular event, DSE ¼ dobutamine stress echo-
cardiography; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; MR ¼ mitral regurgitation; NYHA ¼
New York Heart Association functional classiﬁcation; PCI ¼ percutaneous coronary intervention; PROM ¼
predicted risk of mortality; RV ¼ right ventricular; STS ¼ Society of Thoracic Surgeons; TIA ¼ transient ischemic
attack, TR ¼ tricuspid regurgitation.
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901close the femoral artery percutaneously in the 2 pa-
tients with morbid obesity if they were in an inclined
position. Because of the scar tissue in the groin of the
patient with previous cut down, we were not sure that
the patient could have a percutaneous TAVR and did
not need a repeat cut down. In the last year, 94% of TF-
TAVRs were performed as MA-TF.
PROCEDURAL DATA. All MA-TF patients had a suc-
cessful procedure. One patient required intubation
and intra-aortic balloon pump support due to wire
entanglement of the papillary muscles causing severe
mitral regurgitation. Hemodynamics normalized after
the wire was removed. Three patients in the SA-TF
group had procedure-related deaths (1 patient with
massive aortic insufﬁciency despite a second valve
placement and 2 patients with major vascular com-
plications). There was a trend toward more frequent
TAVR post-dilation in the MA-TF group. Fluoroscopy
time (28  10 min vs. 32  11 min, p ¼ 0.01), proce-
dural time (93  32 min vs. 125  46 min, p < 0.0001),
and room time (150  48 min vs. 218  56 min,
p < 0.0001) were signiﬁcantly less in the MA-TF
group. There was no signiﬁcant difference in con-
trast use. Other procedural variables were similar in
the 2 groups (Table 2).
OUTCOMES DATA. Rates of stroke, bleeding compli-
cations, and new pacemaker implantation were low
and similar between groups (Table 3). Patients in the
MA-TF group had reduced ICU stay and length of
hospital stay. There was no in-hospital mortality with
the MA-TF group, whereas there was 4.2% mortality
in the SA-TF group (p ¼ 0.24). Mortality at 30 days
was not signiﬁcantly different between the 2 groups
(0% in MA-TF group vs. 6% in SA-TF group, p ¼ 0.12).
Moderate or severe paravalvular leak at 30 days was
low and similar in both groups (MA-TF, 3% and SA-
TF, 5.8%, p ¼ 0.4).
In addition to differences in the length of stay, cost
($45,485  14,397 vs. $55,377  22,587, p < 0.001)
(Fig. 2) was signiﬁcantly less in the MA-TF group.
Multivariate predictors of length of stay (Table 4)
included MA-TF, body mass index, abnormal baseline
troponin, hours spent in the ICU, and concomitant
percutaneous coronary intervention (PCI). Multivar-
iate predictors of cost (Table 4) were MA-TF, hours
spent in ICU, length of stay, need for second valve
implantation, concomitant PCI, and urgent proce-
dure. The contribution of each multivariate predictor
to hospital cost was estimated at $2,869 per approach,
$33.37 per ICU hour, $1,032 per hospital day, $27,403
per additional valve, $6,740 for concomitant PCI, and
$7,126 per urgent case (Table 4). At a median follow-
up of 435 days, no signiﬁcant difference was seen insurvival between groups (MA-TF, 83% and SA-TF,
82%, p ¼ NS) (Fig. 3).
DISCUSSION
Our data support an MA-TF strategy for the treatment
of high-risk and inoperable patients with aortic ste-
nosis. The advantage of MA-TF compared with SA-TF
includes a shorter length of stay and a lower initial
TABLE 3 Outcomes
Outcome
Minimalist
Approach
(n ¼ 70)
Standard
Approach
(n ¼ 72) p Value
In-hospital mortality 0 (0) 3 (4.2) 0.24
Patients receiving ICU care 53 (75) 69 (100) <0.001
Total ICU time, h* 22 (2–28) 28 (23–48) <0.001
Length of stay, days* 4 (3–7) 6 (4–9) 0.01
Length of stay: procedure
to discharge, days*
3 (2–4) 5 (3–6.5) <0.001
30-day mortality 0 (0) 4 (6) 0.12
30-day stroke or TIA 3 (4.3) 1 (1.4) 0.35
TIA 0 (0) 1 (1.4) —
Minor stroke 2 (2.9) 0 (0) —
Major stroke 1 (1.4) 0 (0) —
Bleeding
Life-threatening 1 (1.4) 2 (2.8) 1.00
Major 2 (2.9) 3 (4.2) 0.67
Minor 0 (0) 0 (0) NS
Vascular complication 3 (4) 8 (11) 0.30
Major vascular
complication
1 (1) 2 (3) 0.57
Minor vascular
complication
2 (3) 6 (8) 0.27
Concomitant
vascular PCI
3 (4) 4 (6) 0.72
Concomitant
vascular surgery
0 (0) 3 (4.2) 0.24
New left bundle
branch block
4 (6) 5 (7) 0.71
Pacemaker 2 (3) 4 (6) 0.44
30-day echocardiography
Aortic valve area, cm2 1.77  0.46 1.75  0.37 0.79
Aortic valve mean
gradient, mm Hg
10.0  3.3 10.3  5.1 0.68
Mean gradient
<20 mm Hg
70 (100) 66 (96) 0.24
Moderate or severe PVL 2 (3) 4 (5.8) 0.40
Device success 63 (90) 63 (88) 0.79
FIGURE 1 Adaptation of an MA-TF Compared With SA-TF TAVR Over Time
The number of transfemoral transcatheter aortic valve replacement (TAVR)
cases plotted over time from the fourth quarter (Q4) 2010 to the third quarter
(Q3) 2013 are shown. After May 2012, MA-TF largely replaced SA-TF as our
default approach for transfemoral TAVR. MA-TF ¼ minimalist approach to
transfemoral TAVR; SA-TF ¼ standard approach to transfemoral TAVR.
TABLE 2
Ch
Procedure
Procedure
Second va
Concomita
No. of BA
Post-dilat
Coronary
Intubation
Intra-aorti
Conversio
X-ray time
Contrast v
Procedura
Room tim
Values are n
SAVR ¼ s
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902hospital cost without compromising safety or efﬁ-
cacy. Our data suggest that TAVR programs that have
a similar, considerable experience with SA-TF as our
center can safely perform MA-TF.
In 2012, Durand et al. (4) reported a series of 151
patients (SAPIEN, n ¼ 78; SAPIEN XT, n ¼ 73) who un-
derwent TF TAVR safely using only local anesthesia,
conscious sedation, and ﬂuoroscopy. The conversion
rate to general anesthesia was low (3.3%) and only
occurred in patients who had a procedural complica-
tion. In Europe, 40% of TF TAVRs are currently per-
formed in this manner (5,6). At our center, the vastLVEF, % 53  11 52  14 0.58
Blood
Peak creatinine, mg/dl* 1.3 (1.1–1.7) 1.2 (1.0–1.65) 0.19
Peak troponin I, ng/ml* 1.0 (0.50–1.77) 0.85 (0.57–2.67) 0.74
Discharge BNP, pg/l* 256 (130–414) 494 (245–1,219) <0.001
Discharge location
Home 58 (83) 58 (84) 0.84
Extended care 10 (14) 8 (12) 0.63
Other hospital 2 (3) 1 (1) 1.00
Nursing home 0 (0) 2 (3) 0.24
Values are number (%), mean  SD for normally distributed numeric variables,
or median (interquartile range). *Non-normally distributed variables.
ICU ¼ intensive care unit; PVL ¼ paravalvular leak; other abbreviations as
in Table 1.
Procedural Characteristics
aracteristic
Minimalist
Approach
(n ¼ 70)
Standard
Approach
(n ¼ 72) p Value
success 70 (100) 69 (96) 0.24
mortality 0 (0) 3 (4) 0.24
lve implanted 4 (6) 2 (3) 0.43
nt PCI 5 (7) 1 (1) 0.11
Vs performed* 1.7  0.8 2.1  1.3 0.16
ion 27 (39) 16 (22) 0.06
obstruction 0 (0) 0 (0) —
1 (1) 72 (100) <0.001
c balloon pump 1 (1) 2 (3) 0.57
n to SAVR 0 (0) 0 (0) —
, min 28  10 32  11 0.01
olume, ml 126  64 135  73 0.39
l time, min 93  32 125  46 <0.001
e, min 150  48 218  56 <0.001
umber (%) and mean  SD. *BAV numbers include pre- and post-dilation.
urgical aortic valve replacement; other abbreviations as in Table 1.majority of TF TAVR is performed as MA-TF (>96% in
the past 6months). However, there are certain patients
that present a real challenge to performing the MA.
Morbidly obese patients with concomitant comorbid-
ities such as severe lung disease and complex vascular
access, mentally challenged patients, and chronic pain
FIGURE 2 Comparison of Cost in U.S. Dollars Between Mini-
malist Approach and Standard Approach Groups
Hospital costs during the initial procedure hospitalization in the
minimalist approach transfemoral transcatheter aortic valve
replacement (TF TAVR) group compared with standard approach
TF TAVR group. Hospital costs include the cost of the trans-
catheter valve ($32,500) but not physician fees.
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903patients represent this group. Excluding this smaller
cohort of patients, we anticipate that MA-TF will
become very prevalent as centers in the United States
accumulate TAVR experience.TABLE 4 Multivariate Analysis of Length of Stay and Cost
Patient/Procedural Characteristics
Predictors of
Univariate
Estimate p Value E
Standard vs. minimalist approach 6,639 <0.001 2
Age 124.57 0.142
Male sex 787 0.55
STS PROM score 149 0.29
Diabetes 1,581 0.23
Severe COPD 762 0.23
LVEF 8.69 0.853
Atrial ﬁbrillation 12,675 0.002
End-stage renal disease 2,300 0.47
Body mass index 38.6 0.73
Baseline BNP level 0.55 0.46
Abnormal baseline troponin I (>0.4 ng/ml) 1,678 0.29
Vascular complications 9,654 <0.001
Procedure time 98.4 <0.001
ICU stay, h 99.5 <0.001
Postoperative BNP 1.6 0.03
Pacemaker required 5,201 0.12
Length of stay 1,279 <0.001
ICU care required 4,922 0.003
Need for second valve implantation 25,825 <0.001 2
Concomitant PCI 8,982 0.005
Need for urgent procedure 11,263 0.0093
Abbreviations as in Tables 1 and 3. Values of p < 0.05 in the multivariate analysis are iData from this report may help to develop cost-
effective TAVR programs in the United States.
Length of stay ($1,032 per day by multivariate anal-
ysis estimate) has been a main focus for cost
savings in TAVR programs. Same-day admissions for
TAVR and next-day discharge strategies have been
reported (7). We recommend pre-procedure planning
with multimodality imaging (TTE, TEE, and com-
puted tomography) to minimize the risk of a second
valve, and we avoid unnecessary concomitant pro-
cedures (PCI, Swan-Ganz catheter, and Foley cath-
eter). We currently do not send patients to the ICU
after TAVR unless a complication occurs. Balloon
aortic valvuloplasty can be used to avoid urgent
TAVR procedures. The MA-TF strategy decreases the
cost of TAVR ($2,869 estimate) and can be used
frequently to prevent the overhead associated with
hybrid operating rooms and general anesthesia.
We believe that the cost savings realized with the MA-
TF strategy will become even greater with the
approval of newer generation, low-proﬁle TAVR sys-
tems, allowing more patients to undergo TF TAVR
(8,9). Using the above ﬁnancial information, we are
also trying to develop a fast-track protocol for pa-
tients undergoing TAVR in the hybrid operating room
to decrease ICU use, cost, and length of stay.Cost Predictors of Length of Stay
Multivariate Univariate Multivariate
stimate p Value Estimate p Value Estimate p Value
,869 0.002 1.87 <0.001 1.20 0.002
— — <0.001 0.80 — —
— — 0.91 0.02 0.59 0.08
— — 0.13 <0.001 0.04 0.14
— — 0.75 0.07 — —
— — 0.28 0.15 — —
— — 0.01 0.33 — —
807 0.28 0.49 0.35 — —
— — 0.15 0.87 — —
— — 0.11 0.001 0.10 <0.001
— — 0.0007 <0.001 0.0004 0.14
— — 1.17 0.01 1.09 0.006
3093 0.13 1.08 0.10 — —
17.54 0.18 0.01 0.008 0.005 0.24
33.37 0.003 0.03 <0.001 0.03 <0.001
0.57 0.24 0.0011 <0.001 0.0003 0.27
— — 0.13 0.90 — —
1032 <0.001 — — — —
50 0.96 1.61 0.02 0.27 0.57
7403 <0.001 1.16 0.46 — —
6740 <0.001 2.37 0.025 3.15 <0.001
7126 0.002 2.79 0.019 1.21 0.23
n boldface.
FIGURE 3 Kaplan-Meier Survival Analysis of the Treatment Approach in
Relation to the Outcome of Death
No statistically signiﬁcant difference in mortality was seen in the minimalist
approach transfemoral transcatheter aortic valve replacement (TF TAVR)
group compared with the standard approach TF TAVR group after mid-term
follow-up. The corresponding number of patients at risk for each 100-day
interval and the median follow-up for each group are included.
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904STUDY LIMITATIONS. The study limitations of
the data presented here are consistent with limita-
tions of any retrospective study from a single center.
Although we have tried to control for all variables that
may have introduced bias, we recognize that the
experience of the heart team and patient selection
bias could not be controlled for. We performed >100
TAVRs (combined TF and transapical) with the
Edwards Sapien valve before the ﬁrst SA-TF patient
included in this analysis. Thus, the learning curve
associated with new TAVR centers had passed wellbefore the patients reported in this study. We had
performed 300 TAVRs (combined TF and transapical)
before the MA-TF experience was started. The pa-
tients who did not undergo MA-TF after starting our
minimalist program were done in the hybrid room for
scheduling reasons or comorbidities that prevented
lying ﬂat comfortably. However, most patients who
could tolerate routine TF heart catheterization could
also tolerate MA-TF. Differences in baseline B-type
natriuretic peptide levels were not considered clini-
cally important for our patient selection and did not
affect length of stay or cost by multivariate analysis.
Centers that will attempt MA-TF should have appro-
priate experience in TAVR and be responsible with
their patient selection and procedures to maintain
quality and outcomes.
CONCLUSIONS
We report the ﬁrst mid-term mortality outcomes and
cost of an MA to TAVR in the United States. In appro-
priately selected patients, MA-TF is associated with
equivalent safety and efﬁcacy outcomes compared
with SA-TF in a very experienced TAVR center. MA-TF
results in lower costs due to a shorter length of stay and
less resource use. We believe that these results have
important implications for the ﬁnancial viability of
U.S. TAVR programs in the future.
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